AN2 Therapeutics shares surge 10.82% after-hours as Phase 2 trial of epetraborole for M. abscessus lung disease initiates.

AN2 Therapeutics surged 10.82% in after-hours trading following the announcement of the initiation of a Phase 2 investigator-initiated clinical trial for epetraborole in the treatment of Mycobacterium abscessus complex lung disease. The multicenter, randomized, double-blind study, led by Dr. Kevin Winthrop and involving 10–15 U.S. sites, marks a key advancement for the company’s boron-based drug candidate, which targets a serious unmet medical need with no FDA-approved therapies. The trial, with topline data expected in late 2027, highlights the potential for epetraborole to offer a more tolerable and effective treatment option, reinforcing AN2’s position in developing novel therapeutics for infectious diseases.